Physician profile
Amanpal Singh
NPI 1184829749
$1,489.96
in general payments reported to CMS, 2019-2025
13 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $79.90 · 2022: $68.44 · 2023: $240 · 2024: $254 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.42 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $374.49 | 2022-2025 | |
| Abbvie INC. | $225.12 | 2021-2025 | Skyrizi |
| Novo Nordisk INC | $139.41 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $131.33 | 2024 | Resmetirom |
| Janssen Biotech, INC. | $127.78 | 2021-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.23 | 2019-2021 | |
| Gilead Sciences, INC. | $99.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.79 | 2021-2023 | Entyvio |
| Boston Scientific Corporation | $68.41 | 2019-2024 | Orcapod |
| Phathom Pharmaceuticals, INC. | $62.90 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $37.63 | 2025 | Sutab |
| Ardelyx, INC. | $24.39 | 2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $18.43 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanpal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.